METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS
Methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A 2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.
1 . A method of reducing or suppressing the adverse effectiveness of L-DOPA and/or dopamine agonist therapy, comprising administering an effective amount of at least one adenosine A 2A receptor antagonist to a Parkinson's disease patient.
2 . The method according to claim 1 , wherein the patient suffers from L-DOPA- or other dopaminergic-agent-induced motor complications.
3 . The method according to claim 2 , wherein OFF time in motor fluctuations is reduced.
4 . The method according to claim 2 , wherein dyskinesias in motor complications are improved.
5 - 9 . (canceled)
10 . A method for L-DOPA sparing treatment, comprising administering to a patient in need thereof a combination of a sub-clinically effective amount of L-DOPA and one or more adenosine A 2A receptor antagonists in an amount effective to render the L-DOPA efficacious.
11 - 15 . (canceled)
16 . A composition for L-DOPA sparing treatment, comprising a sub-clinically effective amount of L-DOPA and one or more adenosine A 2A receptor antagonists in an amount of effective to render the L-DOPA efficacious.
17 - 21 . (canceled)
22 . A method of treating Parkinson's disease and/or L-DOPA motor complications, comprising administering an effective amount of at least one adenosine A 2A receptor antagonist in combination with a COMT inhibitor and/or DA and/or MAO inhibitor to a patient in need thereof.
23 - 27 . (canceled)
28 . A composition for the treatment of Parkinson's disease, comprising an effective amount of at least one adenosine A 2A receptor antagonist, and a COMT inhibitor and/or DA and/or MAO inhibitor.
29 - 33 . (canceled)
34 . A method of prolonging effective treatment of Parkinson's disease, comprising administering to a patient in need thereof either an adenosine A 2A receptor antagonist or a combination of an adenosine A 2A receptor antagonist and a dopamine agonist in an amount effective to delay or remove the patient's need for add-on L-DOPA therapy.
35 - 42 . (canceled)
43 . A method of treating movement; disorders, comprising administrating an effective amount of at least one adenosine A 2A receptor antagonist to a patient in need thereof.
44 . The method according to claim 43 , wherein the patient suffers from tremors, bradykinesias, shuffling gait, dystonias, dyskinesias, tardive dyskinesias or other extrapyramidal syndromes.
45 - 49 . (canceled)
50 . The method according to claim 43 , wherein the adenosine A 2A receptor antagonist is (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine.